Key Highlights
- Presidential directive issued Saturday instructs FDA to accelerate psychedelic drug evaluations for mental health treatments
- AtaiBeckley stock surged 28% in premarket hours; Compass Pathways advanced 26%
- Commissioner’s National Priority Vouchers will reduce evaluation periods from 6–10 months to 1–2 months for breakthrough therapy candidates
- Ibogaine, currently a Schedule I controlled substance under investigation for opioid addiction treatment, receives special mention in the directive
- Federal commitment of $50 million designated for ibogaine clinical research
The White House issued an executive directive on Saturday instructing the Food and Drug Administration to expedite evaluation processes for psychedelic-based therapies. The measure bears the title “Accelerating Medical Treatments for Serious Mental Illness.”
The mandate applies to therapeutic candidates addressing treatment-resistant depression, post-traumatic stress disorder, and substance abuse disorder.
FDA Commissioner Marty Makary indicated regulatory determinations for certain compounds could arrive by summer 2025.
The directive compresses standard evaluation timelines from 6–10 months to 1–2 months for therapies already carrying “breakthrough therapy” status. This acceleration occurs through Commissioner’s National Priority Vouchers.
Publicly traded psychedelic pharmaceutical developers experienced significant premarket gains Monday morning. AtaiBeckley advanced 28%, Compass Pathways climbed 26%, GH Research increased 19%, Definium Therapeutics gained 15%, Cybin rose approximately 15%, and Enveric BioSciences added 7%.
AtaiBeckley maintains a market valuation near $1.5 billion, positioning it among the sector’s largest publicly traded entities.
Biotech Shares Climb Following Federal Directive
The company’s primary candidate, BPL-003, represents a nasal delivery formulation designed for treatment-resistant depression. Phase 3 clinical trials are scheduled to commence this quarter.
Compass Pathways, a United Kingdom-based biotechnology firm, focuses on COMP360, a synthetic psilocybin compound. The therapy is progressing through advanced-stage clinical studies for treatment-resistant depression and has secured Breakthrough Therapy designation from federal regulators.
The executive directive makes explicit reference to ibogaine, a psychoactive compound extracted from African shrub species. Current federal classification places it in Schedule I controlled substances, indicating regulatory determination of no approved medical applications.
Researchers are investigating ibogaine as a potential intervention for opioid dependency. The order directs regulatory bodies to facilitate access through the Right to Try Act, legislation signed in 2018.
Cardiac toxicity concerns have represented a persistent regulatory challenge for ibogaine development.
Federal Investment and Industry Expert Commentary
The administration announced $50 million in federal funding dedicated to ibogaine clinical investigation.
Jefferies analyst Andrew Tsai characterized the directive as an “official stamp of validation to the class,” emphasizing tangible government backing.
RBC analyst Brian Abrahams described the signing as “a substantial step towards diminishing regulatory risk” for psychedelic pharmaceutical development.
Health Secretary Robert F. Kennedy Jr. has advocated publicly for ibogaine as an alternative intervention for depression and related psychiatric conditions.
Bipartisan congressional members have indicated intentions to advance legislative measures expanding psychedelic therapy accessibility.
FDA Commissioner Makary verified the agency stands ready for rapid implementation under the new framework.
